The Latest Cardiac and Vascular News
AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart donor-derived cfDNA (dd-cfDNA) test to detect rejection in adult and pediatric heart transplant recipients. These are the second and […]
DEDUCE study demonstrates AUC of 0.86 in overall cohort, including more than 700 prospective samples AUSTIN, Texas, April 13, 2022 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its clinical validation study1 on its donor-derived cell-free DNA (dd-cfDNA) test for the assessment of acute rejection in heart transplant patients, […]
Prospera Heart identifies rejection with exceptional performance from a single test, eliminating the need to combine two tests for each patient AUSTIN, Texas, Aug. 31, 2021 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA (cfDNA) testing, today announced the validation and clinical availability of its Prospera Heart […]
